P
Philip L. Lorenzi
Researcher at University of Texas MD Anderson Cancer Center
Publications - 128
Citations - 22127
Philip L. Lorenzi is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Medicine & Biology. The author has an hindex of 37, co-authored 96 publications receiving 17665 citations. Previous affiliations of Philip L. Lorenzi include University of Michigan & Loyola University Chicago.
Papers
More filters
Journal ArticleDOI
Assessment of l-Asparaginase Pharmacodynamics in Mouse Models of Cancer.
Thomas D. Horvath,Wai Kin Chan,Michael A. Pontikos,Leona A Martin,Di Du,Lin Tan,Marina Konopleva,John N. Weinstein,Philip L. Lorenzi +8 more
TL;DR: A new LC-MS/MS bioanalytical method that incorporates rapid quenching of ASNase for measurement of Asn, Asp, Gln, and Glu in just 10 µL of whole blood, with limits of detection estimated to be 2.3, 3.5, 0.8, and 0.5 µM, is presented.
Journal ArticleDOI
Positional stable isotope tracer analysis reveals carbon routes during ammonia metabolism of Aedes aegypti mosquitoes.
TL;DR: Evidence is provided that glucose is used for ammonia detoxification and [13C] uric acid synthesis through multiple metabolic pathways, uncovering a metabolic link at the carbon atomic level in ammonia metabolism of A. aegypti mosquitoes.
Journal ArticleDOI
USP21 deubiquitinase elevates macropinocytosis to enable oncogenic KRAS bypass in pancreatic cancer.
Pingping Hou,Xingdi Ma,Zecheng Yang,Qiang Zhang,Chang-Jiun Wu,Jun Li,Lin Tan,Wantong Yao,Liang Yan,Xin Zhou,Alec C. Kimmelman,Philip L. Lorenzi,Jianhua Zhang,Shan Jiang,Denise J. Spring,Y. Alan Wang,Ronald A. DePinho +16 more
TL;DR: In this article, a deubiquitinase USP21-driven resistance mechanism to anti-KRAS* therapy was identified in pancreatic ductal adenocarcinoma (PDAC) cases.
Journal ArticleDOI
Vestigial-like 1 is a shared targetable cancer-placenta antigen expressed by pancreatic and basal-like breast cancers
Sherille D. Bradley,Amjad H. Talukder,Ivy Lai,Rebecca Davis,Héctor M. Alvarez,Hervé Tiriac,Minying Zhang,Yulun Chiu,Brenda Melendez,Kyle R. Jackson,Arjun S. Katailiha,Heather M. Sonnemann,Fenge Li,Ya'an Kang,Na Qiao,Bih Fang Pan,Philip L. Lorenzi,Mark W. Hurd,Elizabeth A. Mittendorf,Christine B. Peterson,Milind Javle,Christopher A. Bristow,Michael P. Kim,David A. Tuveson,David H. Hawke,Scott Kopetz,Robert A. Wolff,Patrick Hwu,Anirban Maitra,Jason Roszik,Cassian Yee,Gregory Lizée +31 more
TL;DR: It is shown that VGLL1-specific CTLs expanded from the blood of a PDAC patient could recognize and kill in an antigen-specific manner a majority of HLA-A*0101 allogeneic tumor cell lines derived not only from PDAC, but also bladder, ovarian, gastric, lung, and basal-like breast cancers.
Journal ArticleDOI
ATF4 Protects the Heart From Failure by Antagonizing Oxidative Stress
Xiaoding Wang,Guangye Zhang,Subhajit Dasgupta,Erica Niewold,Chao Li,Qinfeng Li,Xiang Luo,Lin Tan,Anwarul Ferdous,Philip L. Lorenzi,Beverly A. Rothermel,Thomas G. Gillette,Christopher M. Adams,Philipp E. Scherer,Joseph A. Hill,Zhao V. Wang +15 more
TL;DR: The findings reveal that ATF4 plays a critical role in the heart under conditions of hemodynamic stress by governing both cytosolic and mitochondrial production of NADPH, a key factor in redox regulation, in pressure overload-induced heart failure.